Storm F K, Gilchrist K W, Warner T F, Mahvi D M
Department of Surgery, University of Wisconsin School of Medicine, Madison.
Ann Surg Oncol. 1995 Jan;2(1):43-8. doi: 10.1007/BF02303701.
The overexpression of heat shock protein 27 (hsp-27) in early-stage breast cancer is associated with histopathologic features of poor prognosis and clinically with an increased probability of disease recurrence. Hsp-27 is overexpressed in 25% of invasive ductal carcinomas (IDC); however, its distribution in ductal carcinoma in situ (DCIS) and DCIS associated with IDC has not been investigated. We postulated that hsp-27 might be detected and variably expressed in DCIS and, like HER-2/neu oncoprotein expression, might be a tumor-specific marker worthy of future clinical investigation.
To test these hypotheses, the distribution of hsp-27 in noncomedo and comedo DCIS, and DCIS associated with IDC, was evaluated by immunohistochemistry and compared with HER-2/neu expression within the same cancers.
Hsp-27 was overexpressed in 28 of 47 (approximately 60%) cases of DCIS; expression in pure DCIS was 16 of 24 (67%), and 12 of 23 (approximately 50%) in DCIS associated with IDC. Hsp-27 expression by in situ and invasive components of the same neoplasm were concordant in 22 of 23 (approximately 95%) cases tested. Comedo variants appeared to have somewhat higher hsp-27 expression than noncomedo DCIS, whether or not there was an associated IDC. These results are reminiscent of HER-2/neu oncoprotein expression in DCIS and DCIS associated with IDC observed by others. However, although 4 of 22 (18%) cancers containing DCIS + IDC expressed HER-2/neu, no relationship with hsp-27 expression in the same cancers was observed.
We found a high incidence of hsp-27 overexpression in DCIS and in DCIS associated with IDC. This rate is twice that previously observed in IDC alone. Hsp-27 expression is independent of HER-2/neu expression.
热休克蛋白27（hsp - 27）在早期乳腺癌中的过表达与预后不良的组织病理学特征相关，在临床上与疾病复发概率增加有关。hsp - 27在25%的浸润性导管癌（IDC）中过表达；然而，其在导管原位癌（DCIS）以及与IDC相关的DCIS中的分布尚未得到研究。我们推测hsp - 27可能在DCIS中被检测到且表达存在差异，并且像HER - 2/neu癌蛋白表达一样，可能是一个值得未来临床研究的肿瘤特异性标志物。
为验证这些假设，通过免疫组织化学评估hsp - 27在非粉刺型和粉刺型DCIS以及与IDC相关的DCIS中的分布，并与同一癌症中的HER - 2/neu表达进行比较。
在47例DCIS病例中的28例（约60%）中hsp - 27过表达；在单纯DCIS中的表达为24例中的16例（67%），在与IDC相关的DCIS中的表达为23例中的12例（约50%）。在23例测试病例中的22例（约95%）中，同一肿瘤的原位和浸润成分的hsp - 27表达是一致的。无论是否存在相关的IDC，粉刺型变体似乎比非粉刺型DCIS具有略高的hsp - 27表达。这些结果让人联想到其他人观察到的DCIS以及与IDC相关的DCIS中的HER - 2/neu癌蛋白表达。然而，尽管在22例包含DCIS + IDC的癌症中有4例（18%）表达HER - 2/neu，但在同一癌症中未观察到与hsp - 27表达的关系。
我们发现hsp - 27在DCIS以及与IDC相关的DCIS中过表达的发生率很高。这一比率是之前仅在IDC中观察到的两倍。hsp - 27表达独立于HER - 2/neu表达。
